Gooreind Pharma
Board
2 directors, no change since 2023Director, permanent representative
since 01-01-2017
term without a fixed end
listed in the 2025 annual accounts, filed on 04-08-2026
Director, permanent representative
since 01-01-2017
term without a fixed end
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 04-08-2026
Permanent representatives 2
Mandates through the years
5 names, the dashed line is todayManager
Manager
Manager
Manager
Manager
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
-
- Manager, from 01-01-2017 to date
-
- Manager, from 01-01-2017 to date
-
- Manager, appointed by deed of 18-01-2017, until 31-12-2021
- Manager, appointed by deed of 18-01-2017, no longer listed in the 2025 annual accounts
-
- Manager, until 01-01-2017
-
- Manager, until 01-01-2017
Control
Parent
Equity €464,321
Profit €101,821 in 2025 (profit €88,245 in 2024)
64.58%
This company
Gooreind Pharma
Equity €390,026
Profit €59,344 in 2025
Capital
- Contribution
- €19,200
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
-
- 2020 to 2021: 20.83%
- 2022 to 2025: 35.42%
-
- 2021: 79.17%
- 2022 to 2024: 64.58%
Source: lists of holdings in the owners' accounts
Articles of association
deed of 23-11-2023 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
Shareholders
2 ownersOwners 2
- parentEquity €464,321 Profit of €101,821 in 2025 (profit of €88,245 in 2024)Sourceaccounts 202564.58%
- Equity €2.7m Profit of €647,955 in 2025 (profit of €224,238 in 2024)Sourceaccounts 202535.42%